As global drug giants grow cautious, can Chinese biotech keep cashing in on out-licensing?

Record-breaking cross-border deals helped make some formerly loss-making Chinese biotech companies profitable in the first half of the year, but multinational drugmakers are now signalling plans to tighten deal budgets. Analysts said deals…